American Journal of Ophthalmology Case Reports (Mar 2021)
Central serous chorioretinopathy treatment with a systemic PDE5 and PDE6 inhibitor (sildenafil)
Abstract
Purpose: Examine the use of systemic phosphodiesterase inhibition (sildenafil) to clear central serous chorioretinopathy (CSCR). Observations: In a long-standing CSCR patient, sildenafil produced a rapid resolution. When discontinued (dechallenge) the CSCR returned. When rechallenged, the CSCR again rapidly disappeared and did not recur in 5 months of continued therapy. Conclusions: AND IMPORTANCE: Systemic sildenafil can cause rapid clearance of CSCR and can augment or replace other treatments.